|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|---|
|
LMSP0502BN07
| |
GalNAcbeta1-3(Fucalpha2-3Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1848.05
|
C88H157N3O37 |
|
LMSP0502BJ07
| |
Galbeta1-3(Fucalpha2-3GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1848.05
|
C88H157N3O37 |
|
LMSP0502BI07
| |
Fucalpha2-3(Galbeta1-4)GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1848.05
|
C88H157N3O37 |
|
LMSP0502AJ07
|
type IV A antigen(d18:1/24:1(15Z))
|
GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1848.05
|
C88H157N3O37 |
|
LMSP0503AL07
| |
GalNAcbeta1-3Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) [SP0503]
|
1848.05
|
C88H157N3O37 |
|
LMSP0503AH07
| |
Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) [SP0503]
|
1848.05
|
C88H157N3O37 |
|
LMSP0504BD07
| |
Galbeta1-4GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1848.05
|
C88H157N3O37 |
|
LMSP0504AM07
| |
Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1848.05
|
C88H157N3O37 |
|
LMSP0504AV07
| |
Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1848.05
|
C88H157N3O37 |
|
LMSP0504AN07
| |
Fucalpha1-2Galbeta1-3GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1848.05
|
C88H157N3O37 |
|
LMSP0505AS07
|
Lex-7(d18:1/24:1(15Z))
|
Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1848.05
|
C88H157N3O37 |
|
LMSP0505AM07
|
type II H antigen(d18:1/24:1(15Z))
|
Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1848.05
|
C88H157N3O37 |
|
LMSP0505CK07
| |
Galbeta1-3GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1848.05
|
C88H157N3O37 |
|
LMSP0505CI07
| |
Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1848.05
|
C88H157N3O37 |
|
LMSP0505AV07
| |
Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1848.05
|
C88H157N3O37 |
|
LMSP0505AH07
| |
Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1848.05
|
C88H157N3O37 |